#CRISPR

Gene editing shows clinical promise for β-thalassaemia in new trial results

A clinical trial has shown that an improved gene editing process can reactivate the fetal hemoglobin gene in β-thalassaemia patients, potentially offering a path away from lifelong blood transfusions.